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Background: Bronchiectasis is a common disabling but rarely fatal disease. However the
long-term prognosis and risk factors for mortality are not well known.
Objective: The aim of this study was to determine prospectively the survival and
predictive factors of mortality in patients with bronchiectasis, during 4-year follow-up.
Patients and methods: From September 2000 to January 2005 survival of bronchiectasis
(as evaluated by computed tomography) and predictors of mortality were assessed in 98
outpatients. Fifty-one of the patients had self-reported history of pulmonary infection
including tuberculosis. Baseline data, reevaluated in every single year according to
scheduled visits.
Results: The mean age was 61710 and 74% of the patients were female. In total, 16
patients (16.3%) died; mean survival time was 44.0671.6 months. The survival rates were
97%, 89%, 76%, 58% at 1, 2, 3 and 4 years, respectively. Cox proportional hazard model
revealed that long-term mortality was significantly associated with age, body mass index
(BMI), Medical Research Council (MRC) dyspnea scale, vaccination, radiographic extent,
hypoxemia, hypercapnia and functional parameters. However, MRC and BMI had more
significant effects on the mortality than the functional parameters.
Conclusions: These results suggest that high BMI, regular vaccination and scheduled visits
may have beneficial effects on the survival of bronchiectasis. Besides, presence of
hypoxemia, hypercapnia, dyspnea level and radiographic extent were more closely
correlated with mortality.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Bronchiectasis is defined as an irreversible dilatation of a
portion of the bronchial tree with destruction of the elastic
and muscular components of their walls, usually due to
recurrent or severe infections. This predisposes to reduction
in the clearance of mucoid and mucopurulent secretions
which causes to reduction in the expiratory flow of air from
the lungs1,2 Bronchiectasis is the result of a broad range of
pathological processes, including primary disorders of
bronchial structure, diseases of mucus clearance, infectious
causes and inflammatory disorders. However, in more than
half of the cases no cause could be found; in an additional
29%, the disease was deemed to be post infectious.3
Regardless of etiology, symptoms include chronic cough,
mucopurulent sputum production, hemoptysis, dyspnea and
tiredness.
High-resolution computed tomography (HRCT), as a non-
invasive gold standard in diagnosis, has revealed that
bronchiectasis has been under diagnosed. For this reason
the exact prevalence of bronchiectasis is unknown but the
incidence has decreased in developed countries with
declining incidence of pulmonary tuberculosis, immuniza-
tion and effective antibiotic treatment in childhood infec-
tions.2,4 The average age at death has also increased during
the last decades and the causes of mortality are now mostly
related to respiratory failure.5 However, it is important to
mention that bronchiectasis remains more common and still
the frequent leading causes of death in many developing
nations. In addition, so many studies have analyzed the
effects of microorganisms in the sputum of patients with
bronchiectasis, a few studies used some of the quality of life
questionnaires to assess the health-related quality of life
status but to date no study has assessed the prospective
long-term predictors and survival analysis of the patients
with bronchiectasis.6–8
The present study was designed to assess prospectively
the mortality rates and potential determinants of mortality
in patients with bronchiectasis during 4-year follow-up.
Therefore patient characteristics related to an increased
mortality rate and preventive factors such as vaccination
were analyzed.
Material and methods
Patients
Subjects were recruited from consecutive patients referred
to the outpatient clinics of a university hospital for
investigation of possible bronchiectasis between September
2000 and January 2004. All of the patients were Caucasians.
We prospectively included all patients who had been
admitted for cough, chronic sputum production and radi-
ological changes consistent with bronchiectasis, in the
study. However, patients with confirmed diagnosis of chronic
bronchitis, bronchial asthma, allergic bronchopulmonary
aspergillosis, cystic fibrosis and previous history of lobect-
omy or pneumonectomy were excluded. The final study
population consisted of patients with bronchiectasis who
had HRCTscan and formal pulmonary function tests (within 1
month time interval), as a result 98 patients (idiopathicbronchiectasis n ¼ 43, postinfective n ¼ 51; 27 of them had
prior tuberculosis, primary ciliary dyskinesia n ¼ 2, a1-
antitrypsin deficiency n ¼ 2) were included and followed
until January 2005. There were 73 females and 25 males
with the mean age (SD) of 61.76710.79 and 74 of them were
non-smoker. All patients gave written informed consent to
participate in the study.Clinical data
The data as follows were recorded for each patient:
anthropometric parameters (including age, gender), medi-
cal history (respiratory symptoms, duration of disease),
smoking history, self-reported comorbidity, previous treat-
ment protocols, frequency of infectious exacerbation per
year, previous number of hospital admission because of
respiratory problems per year and education level. Weight
and height were measured individually, at each visit. Body
mass index (BMI) was calculated by dividing each partici-
pant’s weight in kilograms by the square of the height in
meters. According to calculations, the following standard
classifications were used: o20 kg/m2 (underweight),
X20–24 kg/m2 (normal), X25 kg/m2 (overweight). If there
were former or current smoking history; the number of
cigarette pack-year was calculated as the product of the
period of tobacco use (in years) and the average number of
cigarettes smoked per day. Dyspnea was evaluated accord-
ing to Medical Research Council (MRC) scale, modified by
American Thoracic Society, which is a 5-point scale based on
degrees of various physical activities that precipitate
dyspnea.9 Entire of the patients were instructed about the
cough, daily sputum production and according to their
expressions average of the sputum amount with color were
recorded. Comorbidity was determined by standard methods
(defined as the existence of malignancies, cardiovascular
disease, diabetes mellitus and rheumatologic disease).
Former treatments (such as use of antibiotics, inhaled or
oral steroid, theophylline and bronchodilators) and the
frequency of infectious exacerbations per year were also
recorded from medical data. Besides, the date of hospital
admission was recorded and verified by hospital records in
the first visit.Pulmonary function tests and arterial blood gas
analysis
The functional indices measured were forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC,
peak expiratory flow rate (PEFR), midexpiratory flow rate
(FEF25–75), total lung capacity (TLC), carbon monoxide
diffusing capacity of the lung (DLCO) and adjusted for
alveolar volume (DLCO/VA) were expressed as percentages
of values predicted for the patient’s age, sex and height
using European Community for Steel and Coal (ECSC)
references values.10 Spirometric parameters were measured
using a ‘‘Vmax 229 pulmonary function/cardiopulmonary
exercise testing instruments’’ (SensorMedics, Bilthoven, The
Netherlands) in all patients.
Arterial blood gas (ABG) analyses were performed at rest
and in room air with a Rapid lab 348 pH/Blood Gas Analyzer
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SaO2 were measured while breathing on room air.
Radiology
Computed tomography (CT) scans were obtained on an
electron beam CT scanner (General Electric, USA). Sections
of 1.5 or 3mm thickness were acquired at full inspiration
(10mm intervals) in the supine position. The breath-holding
technique was rehearsed before the HRCT examination and
consecutive scans were of the same section thickness in
individual patients. A high spatial resolution algorithm was
used to reconstruct images that were photographed at
appropriate window settings (level 700 Hounsfield units
(HU); width 1000 HU).
Two observers, 1 radiologist and 1 pulmonologist, indepen-
dently scored each of 6 lobes (the lingula was regarded as a
separate lobe) at the initial CT scanning, as previously
described11–14 using modification of Bhalla system.11 The
presence and extent of bronchiectasis was determined
according to established CT criteria15,16 using a scoring
system as follows: grade 1 ¼ localized bronchiectasis affect-
ing 1 or part of 1 bronchopulmonary segment, grade
2 ¼ bronchiectasis in more than 1 bronchopulmonary segment
(extensive), grade 3 ¼ generalized cystic bronchiectasis.
Follow-up study
In our specialized outpatient clinic the regular follow-up of
each patient were organized according to the scheduled
physician visits and individual cases were usually examined
at for 3–6 months which depends on the situation of the
patients disease status and course. For patients who could
not be followed up, an effort was made to contact the
patient by telephone to obtain information regarding
survival. Also, survival rates were determined at 1–4 years.
Information regarding mortality and cause of death (due to
bronchiectasis and bronchiectasis-related diseases) was
obtained from the medical data or hospital records.
We examined the clinical course and prognosis of the
registered patients. We recorded severity of respiratory
symptoms, treatment history, comorbidity, frequency of
infectious exacerbation, number of hospital admission be-
cause of bronchiectasis per year. Exacerbations were defined
by the presence of 1 or more of the symptoms including
increase in sputum volume or dyspnea, sputum purulence.
Entire of the tests, except HRCT and detailed lung volumes
with diffusing capacity, which were described above was
assessed once a year for every patient. Also, number of
scheduled physician visits per year was recorded for each
year during the follow-up time. Vaccination against influenza
and pneumococci were suggested in every single year and
every 5 years, respectively. Patients were advised to perform
postural drainage at least once a day and increase the
frequency from 2 to 3 times if they suffer an exacerbation.
Statistical analysis
All statistical measurements were made using SPSS Package
for the Social Sciences, Version 11.0 for Windows; SPSS Inc.,
Chicago, IL.Descriptive data are presented as mean7standard devia-
tion or number (percentage). The survival status of all
subjects after 4 years was assessed. The duration from entry
to the last attendance or death was recorded. The
Kaplan–Meier method was used for the evaluation of
prognosis, and the survival time was calculated with this
method.
The Cox proportional hazards model was used to
investigate the effects of clinical variables on survival.
The clinical variables were used as continuous variables,
except that the categorical variables of sex, comorbidity,
the use of oxygen therapy, extent of bronchiectasis,
vaccination were coded numerically as nominal data for
the analysis. Relative risks (RR) were calculated for the
following risk factors; age, sex, BMI, comorbidity, MRC scale,
PFT parameters, ABG analysis parameters, radiological
extent of bronchiectasis, vaccination, frequency of infec-
tions per year, frequency of hospital admissions, number of
scheduled physician visits, long term oxygen therapy.
Results of the analysis were presented in terms of the
estimated RRs with corresponding 95% confidence intervals;
p values of less than 0.05 were considered to be statistically
significant.
Results
Patient demographics and data at presentation
Baseline characteristics, including demographic parameters,
of the 98 bronchiectasis patients at study entry are given in
Table 1. More than 3 quarters of the patients, 75.51%, were
lifetime non-smoker, while the average smoker had an
8.69718.11 pack-year history. A considerably larger propor-
tion of the women were non-smokers and had a higher mean
BMI than the men (po0.001). At the referral time, highest
frequency of patients had 2nd level of dyspnea according to
MRC (n ¼ 56). Almost all patients had a wide range of airway
obstruction with mild hypoxemia. None of the patients had a
previous vaccination for influenza or pneumococci. Only
12.2% of the patients had localized type of bronchiectasis
where as 46.9% of them had bilateral radiographic extent
with cystic bronchiectasis. Additionally half of the patients
had any kind of school education.
Long-term follow up
Follow-up time ranged from 12 to 51 months in overall the
cohort, according to survival time. The pattern of the
functional impairement was combination of obstruction and
restriction. Nevertheless airflow obstruction was the pre-
dominant finding (mean FEV1/FVC 68% predicted and FEV1
45.90% predicted) with radiological extent of bronchiectasis
and there were no significant changes from baseline in any
of the functional variables, which were analyzed during 4-
year study. MRC level was improved in 22 of the patients
whereas 2 significant deterioration were reported. At the
referral time all of the patients had at least 1 hospitalization
history per year but after regular follow-up this became
infrequent. Additionally, 26 of the patients were not
hospitalized because of respiratory symptoms. In serial
chest X-ray observations of 89 patients for each year no
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Table 1 General characteristics of patients with
bronchiectasis.
Patients number (n) 98
Age (yr) 61.76710.79
Sex (female/male) 73/25
BMI (kg/m2) 27.6276.36
Current/former/never smoker (n) 3/21/74
Smoking (pack-year) 8.69718.11
Comorbidity (%) 53(56.1%)
Cardiovascular 19 (19.4%)
Hypertension 21 (21.4%)
Diabetes mellitus 5 (5.1%)
Other comorbidity 8 (10.2%)
FEV1% predicted 45.9717.1
FVC % predicted 55.3717.1
FEV1/FVC % predicted 68.2713.2
TLC % 92.8715.0
DLCO % 73.2712.8
PaO2 (mmHg) 60712
PaCO2 (mmHg) 4177
MRC dyspnea score 2.3370.81
Infectious exacerbations in previous
years (/yr)
2.4071.64
Hospital admissions in previous
years (/yr)
1.6371.83
Scheduled physician visits (/yr) 2.8771.27
Data are presented as mean7SD or number (percentage).
FEV1: Forced expiratory volume in 1 s.
FVC: Forced vital capacity.
TLC: Total lung capacity.
DLCO: Diffusing capacity for carbon monoxide.
Factors related to mortality in patients with bronchiectasis 1393radiographic deterioration were reported. Furthermore, 84
of the patients had regular vaccination for influenza and
pneumococci.
Survival
There had been 16 deaths (16.3%) by the end of the study
and all of these non-survivors died because of bronchiectasis
or bronchiectasis-related disorders (especially respiratory
failure) (Table 2). The mean survival time was 44.0671.6
months. The cumulative survival rates were 97%, 89%, 76%,
58% at 1, 2, 3 and 4 years, respectively. Clinical data of
survivors and non-survivors at the 1st registration are
compared in the Table 3. The Kaplan–Meier cumulative
survival plot for the study population is shown in Fig. 1.
Risk factors for mortality in bronchiectasis
Table 4 shows the results of the univariate analysis for the
influence of risk factors on survival. Mortality was highest in
underweight subjects and decreased with increasing BMI in
both men and women. High values for age, PaCO2, MRC level
and low values for FEV1, FVC and PaO2 were significantly
associated with increased mortality. Furthermore, vaccina-
tion and frequent scheduled physician visits had protec-
tive role whereas mortality was higher with increasingradiographic extent. On the other hand there was no
significant correlation between the treatment protocols
including antibiotics and mortality rates.Discussion
The main findings of the present study, among non-survivors
were; advanced age, hypoxemia, hypercapnia, functional
parameters, dyspnea level and radiographic extent were
associated with increased mortality risk. Among survivors
preventive medicine such as vaccination, scheduled visits
and high BMI may have beneficial effects on the survival rate
of the bronchiectasis patients.
Since 1990s, very limited studies have focused on the risk
factors that influence mortality in patients with bronchiec-
tasis and most of them had a great interest in the respiratory
failure or coexistence with COPD.3,8,18,19 Some of the other
studies have mentioned the microbiologic characterization
or the radiological features of the disease.14,20 Conse-
quently, data on long-term outcomes including preventive
medicine, BMI and dyspnea in outpatients are lacking for
bronchiectasis.
In this study, gender of the cohort was similar to the
recent studies of Nicotra and Dupont18,20 but contrast to
earlier studies.21,22 Besides, never-smoked patients were
higher and the mean age of the total was older than the
reported mean age of the bronchiectasis patients.18,20–23
Our results suggest that non-smoker female dominance is
getting higher day by day without an influence on mortality
of the bronchiectasis. For the same reason, data from the
current study support previous finding that published by
Pasteur et al.3 who demonstrated that ‘lung damages in
bronchiectasis progress at the same rate in both sex.’
The etiology of the bronchiectasis, in a significant
proportion (52%), of our patients was postinfective, includ-
ing tuberculosis. The higher rates of postinfective etiology
that we found may depend on the insufficient childhood
vaccination and tuberculosis disease, which was endemic in
our country.24 This hypothesis could also be supported by the
educational status of our cohort that distinguishes the self-
preventive health care system. Additionally, more than half
of our patients had comorbidity at the referral time and this
percentage was higher than the recent intensive care unit
patients’ of Gursel.8 However, we did not find any influence
of etiology or comorbidity on survival of bronchiectasis. Our
findings could be explained by the fact that our cohort was
perhaps similar in etiology and comorbidity to allow us to
detect the influence of these 2 factors on survival.
The main cause of the death in this study was respiratory
failure, which was considered as directly related to
bronchiectasis. One study on mortality among patients with
bilateral bronchiectasis had reported that the 1-year
mortality rate after intensive care unit stay was 40% and
also the main cause of the death was respiratory failure.18 In
another study, Keistinen et al.17 took into account a higher
number of patients (n ¼ 842) which were gathered from
multiple hospitals of the country and the 9 years mortality
rate was 25%. The current findings regarding long-term
mortality are somewhat different. This difference may be
due to different methodologies employed, use of longer
follow-up period and stage of the disease. Furthermore, the
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Table 2 Characteristics of non-survivor patients with bronchiectasis.
Patient Age (yr) Follow-up time
(months)
Place of death Cause of death, from death
certificate
1 75 41 Hospital Pulmonary arrest
2 75 50 Hospital Pulmonary arrest
3 70 27 Hospital Pulmonary arrest
4 73 28 Hospital Pulmonary arrest
5 74 24 Hospital Pulmonary arrest
6 75 27 Hospital Cardio-pulmonary arrest
7 51 48 Hospital Pulmonary arrest
8 70 24 Hospital Cardio-pulmonary arrest
9 73 36 Hospital Pulmonary arrest
10 72 14 Hospital Pulmonary arrest
11 62 12 Home Cardio-pulmonary arrest
12 70 24 Hospital Pulmonary arrest
13 85 27 Hospital Pulmonary arrest
14 58 24 Hospital Cardio-pulmonary arrest
15 73 18 Hospital Pulmonary arrest
16 77 27 Hospital Pulmonary arrest
Cause of death: There was no additional cause for pulmonary or cardiopulmonary arrest other than bronchiectasis.
Table 3 Comparison of backgrounds of survivors and non-survivors.
Variables Survivors (n ¼ 82) Non-survivors (n ¼ 16) p value
Age (yr) 59.74710.11 72.0678.07 o0.0001
Female/male (n) 61/21 12/4 1.0
BMI (kg/m2) 29.5474.94 17.6872.06 o0.0001
MRC dyspnea score 1.6970.62 3.8170.40 o0.0001
FEV1 (%) 46.99717.75 40.50712.50 0.09
FVC (%) 56.36717.68 50.00713.27 0.11
FEV1/FVC 68.29712.90 67.73715.14 0.87
PaO2 (mmHg) 62.26712.11 52.5779.17 0.001
PaCO2 (mmHg) 40.8676.95 45.5476.78 0.01
Infectious exacerbations in previous years (/yr) 2.4271.69 2.3171.35 0.77
Radiographic extent (1/2/3) 12/38/32 0/2/14 0.002
Vaccinated/non-vaccinated patients (n) 79/3 5/11 o0.0001
Data presented as mean7SD or number (percentage).
1 ¼ localized bronchiectasis, 2 ¼ bronchiectasis in more than one bronchopulmonary segment, 3 ¼ generalized cystic
bronchiectasis.
Z.P. Onen et al.1394survival of our patients remains poor with a 4-year
cumulative survival rate of 58%.
A few studies have referred to the nutritional status in
respiratory failure including bronchiectasis patients but it
has not been demonstrated that malnutrition is associated
with poor prognosis in patients with bronchiectasis.25
Additionally, results of our study are in contrast to those
of Dupont who found low BMI, was not associated with
mortality in their retrospective analysis of intensive care
unit patients with bilateral bronchiectasis.18 A possible
explanation could be that entire of their study population
had edema related to right ventricular failure at the referral
time. For this reason BMI may has been overestimated and
has lacked predictive ability in the survival of their study
cohort. In our study population, BMI was independently
significant predictor of survival and long-term mortality; thecritical level appeared to be 20 kg/m2, below which
mortality rate increased. The suggested mechanism for
higher long-term mortality in patients with lower BMI may
be impaired immune response with respiratory muscle
weakness. Also, this situation may be attributable to the
raised systemic markers of inflammation such as high
sensitive CRP but in our study population the relationship
was not significant. We have not specifically measured the
influence of inflammation and future studies should inves-
tigate the impact of systemic inflammation on long-term
mortality of bronchiectasis.
Although, dyspnea is 1 of the main symptoms of the
bronchiectasis, until know limited studies have suggested
that dyspnea could be used as 1 of the prognostic factors in
patients with bronchiectasis. Garcia reported that the
dyspnea is the most relevant health-related quality of life
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Figure 1 Kaplan–Meier curve showing cumulative survival rates of 98 patients with bronchiectasis during study period.
Table 4 Cox proportional hazards analysis for factors associated with mortality in bronchiectasis.
Parameters RR (95% CI) p value
Age (yr) 1.14 (1.07–1.21) o0.001
BMI (kg/m2) 0.71 (0.61–0.83) o0.001
FEV1 (%) 0.98 (0.91–1.00) 0.05
FVC (%) 0.96 (0.93–1.00) 0.04
PaO2 (mmHg) 0.94 (0.90–0.99) 0.01
PaCO2 (mmHg) 1.11 (1.03–1.2) 0.007
Radiographic extent 5.29 (1.19–23.54) 0.02
MRC dyspnea scale 5.73 (2.55–12.85) o0.001
Scheduled physician visits (/yr) 0.41 (0.25–0.67) o0.001
Vaccination 10.1 (3.41–29.88) o0.001
Data presented as mean7SD or number (percentage).
CI ¼ confidence interval.
Factors related to mortality in patients with bronchiectasis 1395(HRQL) as assessed by the St. George’s Respiratory Ques-
tionnaire (SGRQ) and scale of MRC in stable bronchiectasis.6
In our study population, functional dyspnea; as measured by
the modified MRC scale correlated similarly with mortality
at the initial visit. Besides, MRC scale was also associated
with an increased risk of death at the end of the follow-up
time period. The present study suggest that categorization
by the level of dyspnea may be useful in the prediction of
survival in bronchiectasis.
To date limited studies on the prognosis of patients with
bronchiectasis have utilized a few objective radiological
indexes as factors related to survival.12 After the confirma-
tion of the diagnosis of bronchiectasis, radiological extent
may be preferred for the estimation of survival rate.
Leading practical theories for determining the radiological
extent can be modified by Bhalla system,11 which may beperformed by clinicians. To the authors’ experience,
observer variation for HRCT features was generally accep-
table in this system. Although convincing explanation for
these results are difficult to construct, almost half of the
patients had high modified Bhalla scores, which increased
the mortality rates 5.29 folds compared with the patients
who had low scores, those may be responsible for the
results.
An interesting finding in our analysis was that, among all
predictor factors, impact of concerning spirometric data on
mortality was poor or not influential with univariate
analysis. On the other hand, authors were expecting to
see restrictive changes more frequently than the obstruc-
tion in pulmonary function, according to underlying
abnormality. The precise mechanisms are unknown but
may be related to the radiological features and extent of
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pattern is obstructive, whereas in the presence of atelec-
tasis the abnormality in function may be restrictive. Another
possibility is that, there was no significant alteration from
the baseline in the spirometric data during follow up. In any
case, our results would confirm the recent hypothesis of
Garcia et al.6 that, the FEV1 was the weakest predictive
factor on mortality of bronchiectasis.
Among non-survivors, 75% of the patients had hypercapnia
whereas 17% of the survivors had hypercapnia. A high PaCO2
was found to be a risk factor for mortality in our population
and this is in line with other reports.26 The level of
hypercapnia reflects the severity of the underlying condi-
tion. Because of this reason, patients with chronic hyper-
capnia during follow-up time have a worse prognosis than
patients with normocapnia. On the other hand, PaO2 has also
correlated with survival and confirmed the results of Stro¨m
and Boe27 Among all predictive factors on long-term
improvement investigated by univariate analysis PaO2 and
PaCO2 were found independently prognostic factors.
The most surprising finding in the present study was the
strong independent association between regular vaccination
and preventive influence on the mortality of bronchiectasis.
Although, numbers of respiratory infections were associated
with an inflammatory response and the release of proteo-
lytic enzymes, which results in damage to the airway wall,
the relationship between immunization and survival has not
been researched. Besides, the prognostic value of regular
vaccination in patients who were treated with conventional
treatment is more difficult to explain, because there is not
enough study available to compare with the present study in
directly addressing immunization and the long-term survival
of bronchiectasis patients.
Although the present study has the advantage of being
based on a large and prospectively examined population
with a long duration of long-term follow-up it also has
shortcomings. First, some factors that probably could be
predictors of reduced survival, such as bacterial coloniza-
tion of sputum, 6min walking test and pulmonary arterial
pressure were not assessed. Second, our study was not
designed to test whether the inhaled steroids and antibiotic
treatments were different in their predictive validity.
On the basis of the present study of subjects with
bronchiectasis we conclude that underweight and MRC scale
are important independent risk factors for mortality, both of
them are simple to calculate and requires no special
equipment or time. Although, functional parameters had a
significant influence on the mortality, the findings of this
study will have a potentially great impact of the radiological
extent in bronchiectasis from the perspective of survival. In
addition to this, vaccination and scheduled physician visits
had preventive effects on the mortality but we do not know
whether these would be useful indicators of the outcome in
clinical trials. Moreover, future studies should focus on
preventive medicine that will improve health-related
quality of life in bronchiectasis.Acknowledgments
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